Evidence map›Paper›PMID 39003366›Full record

Trial reportInternational urology and nephrology2025

Evaluation of platelet-rich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study.

Adham Zaazaa, Mohamed Abbas Eid, Sameh Fayek GamalEl Din, Ashraf Zeidan, Ahmed AbdEl Hakeem, Mohamed Abdel Fattah Farag, Ahmed Fawzy, Amr Kaddah

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adham ZaazaaDepartment of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt.
Mohamed Abbas EidDepartment of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt.
Sameh Fayek GamalEl DinDepartment of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt. samehfayek@kasralainy.edu.eg.ORCID http://orcid.org/0000-0003-1918-5132
Ashraf ZeidanDepartment of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt.
Ahmed AbdEl HakeemEgypt Ministry of Health and Population, Cairo, Egypt.
Mohamed Abdel Fattah FaragDepartment of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt.
Ahmed FawzyDepartment of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt.
Amr KaddahDepartment of Andrology, Sexology and STDs Kasr Al-Ainy, Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe studied the effect of a platelet-rich fibrin matrix (PRFM) combined with prostaglandin E-1 (PGE-1) injection on erectile function in patients refractory to response for phosphodiesterase type 5 inhibitors (PDE5-Is).

methodsThis randomized, double-blind, placebo-controlled study included 80 patients. The patients were randomly assigned to four groups and blinded together with the administrating physicians to the nature of the intracorporeal injection (ICI) therapies. Group (1) received saline, group (2) received platelet-rich fibrin matrix (PRFM), group (3) received prostaglandin E-1 (PGE-1), and group (4) received a combination of PRFM + PGE-1. The patients received ICI therapy weekly for 8 consecutive weeks. Clinical information and follow-up data were obtained at 1, 2, 3, and 6 months.

resultsA significant increase occurred in the validated Arabic version of the International Index of Erectile Function (ArIIEF-5) score in group (4) compared to the other three groups (p value = 0.037). There was a significant difference in erection hardness scale (EHS) scores among all groups after receiving the different treatments (p = 0.004). A significant increase was seen in the ArIIEF-5 score in groups 4 and 3 compared to that in groups 1 and 2 (p < 0.001). There was also a significant increase in the arterial dilatation % in groups 4 and 3 compared to that in groups 1 and 2 (p = 0.019).

conclusionThe combination of PRFM plus PGE-1 had shown significant improvement in the ArIIEF-5 score, yet the patients still had mild to moderate ED.

Indexed as

AlprostadilErectile DysfunctionPenile ErectionPhosphodiesterase 5 InhibitorsPlatelet-Rich FibrinAdultAgedDouble-Blind MethodHumansInjectionsMaleMiddle AgedVasodilator AgentsAlprostadilPhosphodiesterase 5 InhibitorsVasodilator AgentsErectile dysfunctionIntracorporeal injectionPGE-1Platelet-rich fibrin matrixRefractory response to PDE5-IVasculogenic erectile dysfunction

Identifiers

PMID39003366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.